8:00 am
Networking & Registration

8:25 am Chair’s Opening Remarks

Investigating Targeted Therapeutic Approaches Against Alzheimer’s

8:30 am Targeting Abeta Oligomer Formation Using Small Molecules


  • Hearing how the amyloid pathway has emerged as a druggable target for Alzheimer’s disease
  • Understanding how antibody therapies can be used to showcase efficacy against the amyloid pathways
  • Discovering how small molecules can offer complementary alternatives to antibodies and an new therapeutic approach against Alzheimer’s

9:00 am Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s

  • David Bearss Chief Scientific, Officer, Halia Therapeutics


  • Learning how persistent NLRP3 inflammasome signaling propagates neuroinflammation in aged brains, and promotes AD pathogenesis and progression
  • Hearing how recent data confirms the essential role of NEK7 in the assembly of NLRP3 complex
  • Discovering how Halia is the first to target NEK7 to block the formation of NLRP3 inflammasome complex

Exploring the Evolution of the Regulatory Landscape & Learning How to Tailor Your Drug Development Approach for Swift Approvals

9:30 am Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease


  • Discussing & debating whether biopharma should strive to achieve disease modification or improvement in quality of life when developing therapies for Alzheimer’s
  • Exploring the impact of Aducanumab on international approval for neurodegenerative disease
  • Learning what steps you must take to tailor your drug development approach to meet regulatory standards

10:15 am
Morning Break & Networking

Deep Diving into Therapy Delivery Across the Blood Brain Barrier to Drive Therapeutic Success

11:00 am Analyzing Translational Approaches for Brain Targeted Drug Delivery

  • Lisa Shafer Chief Scientific Officer, Cerebral Therapeutics


  • Exploring challenges, success’ and failures in drug distribution for neurodegenerative disease
  • Understanding what steps you must take to enable personalized dosing and designing a biomarker strategy which works across neurodegenerative disease indications
  • Hearing common mistakes in effective clinical translation of therapeutic delivery across the blood brain barrier and learning how to overcome them

11:30 am Introducing a Novel Drug Assessment Through Brain Microdialysis Examining BBB Permeability


  • Scrutinizing the blood brain barrier to pinpoint what factors make therapeutic delivery across it challenging and learning how you can tailor your therapeutic design to work alongside it
  • Comprehensively explaining the BBB permeability test and how it can be utilized to assess and upgrade blood brain barrier permeability
  • Uncovering the revolutionary power of microdialysis for the BBB and discovering it’s potential to transform therapeutic delivery across the blood brain barrier

12:00 pm
Lunch Break & Networking

Discovery & Translational Track

Closing the Translational Gap: Update on Neurodegenerative Disease Models & Imaging

  • Phllip Kong Associate Director for Translational Medicine, Alector

1:00 pm Discovery of Small Molecule Dual Inhibitors of Abeta & Tau Aggregation Using CCM Technology


  • Understanding why the link between oxidation and aggregation of DJ-1 and its loss of function as relevant to the onset of familial and sporadic Parkinson’s disease
  • Evaluating of various oxidized states of DJ-1 as biomarkers for Parkinson’s disease using novel ELISAs
  • Targeting DJ-1 by novel pharmacological chaperonesn as a therapeutic approach for Parkinson’s disease

1:30 pm In Vitro Transcytosis Models for BBB targeting CNS Drug Screening


  • Outlining challenges with in vitro models for neurodegenerative drug development and learning the key attributes for a good model
  • Developing in vitro models for different species
  • Utilizing in vitro models for BBB targeting neurodegenerative drug screening

2:30 pm Exploring the Generation of Vascularised & Perfusable Brain Organoid for Disease Modelling

  • Raphael Lis Assistant Professor in Regenerative & Reproductive Medicine & Director of the Starr Foundation Stem Cell Derivation Laboratory, Weill Cornell Medicine


  • Understanding the importance of cell identity in a given model in the context of neurodegenerative drug development
  • Reproducability 101: Understanding what factors you must consider when designing models to maximize reproducability of therapeutic outcomes in a clinical setting
  • Understanding the role of vascularization in CNS disorders and learning how to incoorporate this into neurodegenerative disease models

Late Translational & Early Clinical Track

Analyzing the Latest Biomarkers Research to Determine Which One is the Most Useful for Neurodegenerative Disease Drug Development

1:00 pm How to Define Patient Selection, Selection of Optimal Intervention Points & Therapeutic Outcomes Using Biomarkers & “Prodromal AD”


  • Learning tips and tricks to streamline the use of “biomarkers” for patient selection
  • Using longitudinal biomarker measures of high scientific interest in the field to augment the use of ‘clinical/cognitive efficacy” outcomes
  • Uncovering data driven methods to optimize the selection of patient and protocol duration and endpoints

1:30 pm Audience Discussion: Understanding What Features the FDA/EMA Assess When Approving Biomarkers in the Context of Neurodegenerative Disease Drug Development


The difference between a successful and unsuccessful clinical trial can come down to what biomarker you choose to measure the efficacy of your therapeutic. It is critical to play close attention to just what features your selected biomarker must possess to optimize the success of your novel therapeutic in a clinical setting. Join this structured audience discussion to debate how to strategically select your next neurodegenerative biomarker in line with FDA/EMA guidelines. Learn how to optimize your approach to tackling common challenges associated with utilizing biomarkers in neurodegenerative drug development.

2:30 pm Fluid & Imaging Biomarkers in ALZ-801 Development: A First-in-Class Oral Disease Modifying Agent for Alzheimer’s Disease

  • John Hey Chief Scientific Officer, Alzheon


  • Harnessing the power of fluid biomarkers and imaging modalities as diagnostic and theragnostic biomarkers in drug development for Alzheimer’s disease
  • Revealing novel Alzheimer’s biomarkers used in modification trials and understanding their impact on disease modification trials
  • Comparing and contrasting CSF versus plasma biomarkers on disease progression and severity

3:00 pm Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks


  • Hearing how new mechanisms and modalities have opened doors for early stage investment
  • Exploring new regulatory approvals, and their effect on the funding environment for clinical stage opportunities
  • Public market reception for neuro focused companies, and the effect on M&A

3:30 pm End of Day Two